metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus ipilimumab alone
	pembrolizumab (10mg/kg) vs. ipilimumab alone	1	-812 [-1640; 16] /10000 119/277 vs. 142/278	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
	pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone	1	-735 [-1562; 92] /10000 122/279 vs. 142/278	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
versus Standard of Care (SoC)
	pembrolizumab (10mg/kg) vs. Standard of Care (SoC)	1	-687 [-1647; 274] /10000 117/181 vs. 128/179	-1698 [-2533; -862] /10000 126/181 vs. 155/179	-
	pembrolizumab (2mg/kg) vs. Standard of Care (SoC)	1	-318 [-1266; 631] /10000 123/180 vs. 128/179	-1493 [-2319; -666] /10000 129/180 vs. 155/179	-